Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Glioma 1Advanced Non-small Cell Lung Cancer 1

Interventions

Gemcitabine 17pembrolizumab 16Cisplatin 14enfortumab vedotin 7avelumab 7Nivolumab 6Docetaxel 6atezolizumab 5Paclitaxel 5Cystectomy 5sacituzumab govitecan 4durvalumab 4Mitomycin 4Cystoscopy 4Carboplatin 4vofatamab 3tremelimumab 3Radiotherapy 3Magnetic Resonance Spectroscopy 3vinflunine 2tisotumab vedotin 2poly ICLC 2cemiplimab 2aldesleukin 2Transurethral Resection of Bladder 2Radiotherapy, Intensity-Modulated 2Ipilimumab 2Interleukin-2 2Immunoglobulin G 2Clinical Trials, Phase II as Topic 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Urinary Bladder Neoplasms × Platinum Compounds × Clear all
NCT04851834 2022-12-20

NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma

Xennials Therapeutics Australia Pty Ltd

Phase 1/2 Terminated
12 enrolled
CNSGenitourinaryGynecologic

Urinary Bladder Neoplasms, Glioma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡